Otify, E. A. A. A., Nunney, I., Dhatariya, K. and Stather, P. W.
ORCID: https://orcid.org/0000-0002-3585-6728
(2026)
The Combined Effect of Renin Angiotensin System Blockade and Metformin on Abdominal Aortic Aneurysm Growth Rate in People with Diabetes Mellitus—A Propensity-Matched Retrospective Cohort Study.
Annals of Vascular Surgery, 129.
pp. 404-411.
ISSN 0890-5096
|
Microsoft Word (OpenXML) (Metformin and ACEARB 0226)
- Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (48kB) |
Abstract
Background: Identification of a safe and effective medical therapy for abdominal aortic aneurysm (AAA) remains a significant unmet clinical need. This study evaluated the associations between commonly prescribed medications in type 2 diabetes mellitus (T2DM), HbA1c measurements, and AAA growth over a 14-year surveillance period. Methods: A retrospective cohort study including all patients enrolled in the AAA screening and surveillance program at Norfolk and Norwich University Hospital NHS Foundation Trust. Records of AAA size, risk factors, medications, outcomes, complications, and mortality were analyzed. A 1:1 propensity matching was undertaken to validate results. Results: The study comprised 986 patients (84.7% male), of whom 199 had T2DM. The mean initial AAA diameter did not differ significantly between groups (39.3 mm [standard deviation (SD) 7.2] in T2DM versus 39.4 mm [SD 6.9] in non-T2DM; P = 0.68). Patients with T2DM had a significantly lower mean AAA growth rate (2.2 mm/year [SD 3.1] vs. 2.7 mm/year [SD 2.9]; P = 0.042). The mean follow-up duration was longer in the T2DM group (5.2 years [SD 3.6] vs. 4.6 years [SD 3.3]; P = 0.03). Use of metformin and angiotensin-converting enzyme inhibitor/angiotensin II receptor type I blocker therapy was independently associated with reduced AAA growth rates (1.40 mm/year, 95% confidence interval [CI] 1.05–1.88; and 1.67 mm/year, 95% CI 1.52–1.83, respectively). Combined therapy was associated with the greatest reduction (1.19 mm/year, 95% CI 0.97–1.47) compared with neither medication (1.94 mm/year, 95% CI 1.78–2.12). These findings remained significant after 1:1 propensity score matching. Conclusion: Metformin and ACEi/angiotensin II receptor type I blocker therapy are associated with reduced AAA growth rates, with the greatest protective effect observed in patients receiving combined therapy.
| Item Type: | Article |
|---|---|
| Additional Information: | Availability of the data and materials: Dio and hyperlinks present, both original data generated within this research and secondary data used that supports the results and analyses. |
| Uncontrolled Keywords: | surgery,cardiology and cardiovascular medicine,sdg 3 - good health and well-being,das in place,availability of the data and materials: dio and hyperlinks present, both original data generated within this research and secondary data used that supports the results and analyses.,2026 ,/dk/atira/pure/subjectarea/asjc/2700/2746 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 17 Nov 2026 16:09 |
| Last Modified: | 17 Nov 2026 16:11 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/105136 |
| DOI: | 10.1016/j.avsg.2026.03.010 |
Downloads
Downloads per month over past year
Actions (login required)
![]() |
View Item |
Tools
Tools